8 Diabetes Myths, Corrected: Sugar, Rice, Insulin and Quick Cures

Eight common diabetes myths in India — about sugar, rice, insulin, fruit and quick cures — corrected with evidence, plus how common diabetes really is.

Diabetes attracts more myths than almost any other condition — about sugar, rice, fruit, insulin and quick cures. Believing them can delay good care. Here are eight common ones, corrected with evidence, followed by a look at how common diabetes really is.

Eight diabetes myths, gently corrected.

Diabetes is one of the most misinformation-heavy areas of medicine — from "sugar causes diabetes" to "reversal is impossible" to "insulin means you failed." Here are eight of the most-common myths we hear, and what the research actually shows.

Myth

"Type 2 diabetes is progressive — you'll be on more and more pills forever."

Fact

Historically true, but DiRECT (Lean 2018) changed the picture. 46% of T2DM patients diagnosed within 6 years achieved full remission (HbA1c <6.5% off all diabetes medications) at 12 months with structured weight loss. Remission depends on early diagnosis, weight loss ≥10 kg, and preserved beta-cell function. Not everyone can achieve remission but many can — worth trying if you fit the profile.

Myth

"Sugar causes diabetes — I got it because I ate too many sweets."

Fact

T2DM is caused by a combination of genetics + insulin resistance driven by visceral adiposity + progressive beta-cell dysfunction. Sugar intake isn't a direct cause, though sugar-sweetened beverages contribute to weight gain which drives insulin resistance. The primary levers are total calorie intake, physical activity, and weight — not sugar specifically. T1DM has no dietary cause at all (autoimmune).

Myth

"If I start insulin, that means I've failed at managing my diabetes."

Fact

T2DM is progressive for many — beta-cell function declines ~4% per year (UKPDS) even with perfect management. Needing insulin over time is often biology, not failure. Modern analogue insulins with CGM produce excellent control with minimal hypoglycemia. Sometimes insulin is temporary — used to break glucotoxicity, then de-escalated back to oral agents.

Myth

"GLP-1 drugs (, ) are just weight-loss shortcuts — I should lose weight the natural way first."

Fact

GLP-1 receptor agonists were developed for T2DM and produce dramatic weight loss AND cardiovascular protection (SELECT 2023 showed 20% MACE reduction in adults with CVD without diabetes). They're not a shortcut — they treat the underlying biology of insulin resistance and appetite regulation. Lifestyle change alongside is still essential; GLP-1s make sustained lifestyle change possible for many.

Myth

"Natural remedies (bitter gourd, methi, cinnamon) can control diabetes without medications."

Fact

Some supplements show modest glucose-lowering effects in small studies (methi seeds ~0.3% HbA1c, cinnamon inconsistent) but none replaces evidence-based medication for established T2DM. Delaying real treatment while relying on supplements risks preventable complications. Lifestyle (diet, weight, activity) is powerful and worth prioritising; supplements are optional add-ons at best.

Myth

"My HbA1c is 8.5% — I feel fine, so it's not urgent."

Fact

Diabetes damages vessels silently for years before symptoms appear. HbA1c 8.5% means average glucose ~200 mg/dL — driving microvascular damage (retina, kidney, nerves) and accelerating atherosclerosis. Most complications only become noticeable after years, when they're harder to reverse. Every 1% HbA1c reduction reduces microvascular complications by ~35% (UKPDS 33).

Myth

"Thin people don't get diabetes."

Fact

Lean T2DM exists, especially in South Asians who develop insulin resistance at lower BMI (Asian Indians can have T2DM at BMI 22-25). LADA (Latent Autoimmune Diabetes in Adults) is autoimmune T1DM presenting in adults, often lean. MODY (Maturity-Onset Diabetes of the Young) is a monogenic form in young lean patients. Any adult with unexplained hyperglycemia deserves proper diagnosis (fasting insulin + C-peptide + GAD-65 antibodies) — not assumption.

Myth

"diabetes care is second-best — I need to see a doctor in person."

Fact

Telemedicine has been validated in ADA Standards of Care since 2021. For management — medication titration, CGM review, education, coordination, results interpretation — is equivalent to in-person, sometimes better (more frequent contact possible, no travel, results uploaded automatically). What still needs in-person: annual dilated eye exam, foot exam with monofilament, acute complications.

Believed a myth for years? Not your fault. Modern diabetes care changes fast.

Just how common and treatable diabetes really is.

India has the second-largest diabetes population globally (after China), with 74 million adults living with T2DM and another 136 million with prediabetes (ICMR-INDIAB 2023). Despite that, awareness and treatment gaps remain massive — half of adults with diabetes are undiagnosed, and only a third of the diagnosed achieve HbA1c targets. The numbers below are worth knowing: this is a highly common, highly treatable condition — and the tools to actually reverse it in early T2DM now exist.

537M

Adults with diabetes globally

IDF Diabetes Atlas 2021 — projected to 783M by 2045

74M

Adults with diabetes in India

ICMR-INDIAB 2023 — 2nd highest globally, projected 125M by 2045

136M

Indians with prediabetes

ICMR-INDIAB 2023 — highly reversible with DPP-style intervention

46%

T2DM remission with DiRECT protocol

Lean et al. Lancet 2018 — at 12 months in early T2DM patients

58%

Prediabetes progression reduction with DPP

Knowler et al. NEJM 2002 — with 7% weight loss + 150 min/wk activity

38%

CV mortality reduction with SGLT2i

Zinman et al. EMPA-REG OUTCOME NEJM 2015 in T2DM+CVD

~50%

Adults with diabetes are undiagnosed

IDF Atlas 2021 — global average; India ~50-55%

1 in 3

Adults meet HbA1c target

Various country registries — huge room for improvement worldwide

Sources: International Diabetes Federation Atlas 2021 (10th edition) · ICMR-INDIAB Study 2023 (Anjana et al., Lancet Diabetes Endocrinol) · Lean MEJ et al. DiRECT (Lancet 2018) · Knowler WC et al. Diabetes Prevention Program (NEJM 2002) · Zinman B et al. EMPA-REG OUTCOME (NEJM 2015) · UKPDS 33/34 (Lancet 1998) · Ramachandran A et al. IDPP-1 (Diabetologia 2006) · ADA Standards of Care in Diabetes 2025.

One person less in the "undiagnosed" column

These are big numbers. But your outcome is individual.